Business Insight

Catalent Investor Relations

1 732 537 6325 Fax. Investors Novavax Inc.


Catalent Biologics Full Overview Brochure

From 2016 to 2019 having previously served as that companys President.

Catalent investor relations. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. 14 Schoolhouse Road Somerset NJ 08873 Phone. Investor Presentation January 11 2021.

1 732 537 5932 Mail. 1 732 537 6325 Fax. A strong balance sheet to position Catalent in the best possible way to navigate through these challenging times.

1 732 537 5932 Mail. Tycho Peterson JP. Employer Identification No 14 Schoolhouse Road Somerset NJ 08873 Address of principal executive offices Zip.

Aug 30 2021. 1 732 537 6325 Fax. Castellano will continue to oversee Catalents FPA group and remain Treasurer of the Company.

Karen Flynn was named President Biologics and Chief Commercial Officer in 2020. Investor Relations Dept Catalent Inc. Arcturus Therapeutics Holdings Inc.

Investor Relations Dept Catalent Inc. 1 732 537 6325 Fax. This presentation contains both historical and forward-looking statements.

1 732 537 5932 Mail. Investor Relations Dept Catalent Inc. In the first few months of fiscal 2021 weve already announced significant investments including.

Paul Surdez Vice President of Investor Relations. John Chiminski Chair and Chief Executive Officer. Jacob Johnson Stephens Analyst.

Thomas Castellano Senior Vice President and Chief Financial Officer. 1 732 537 5932 Mail. Richard Kerns 44 0 161 728 5880 richardnepragency.

Working on 80 compounds for 60 customers across our global network. An additional investment of 130 million. Exact name of registrant as specified in its charter _____ Delaware 20-8737688 State or other jurisdiction of incorporation or organization IRS.

14 Schoolhouse Road Somerset NJ 08873 Phone. 14 Schoolhouse Road Somerset NJ 08873 Phone. Our leadership team continues to execute our strategic plans with urgency.

Investor Relations Dept Catalent Inc. 14 Schoolhouse Road Somerset NJ 08873 Phone. All statements other than statements of historical fact are or may be deemed to be forward-looking statements within the meaning of Section 27A of the.

Catalent on Track to Produce Over One Billion Doses of Covid-19 Vaccines and Therapies. Paul Surdez 1 732 537 6325 Moderna Media. KAREN FLYNN PRESIDENT BIOLOGICS AND CHIEF COMMERCIAL OFFICER.

Investor Relations Dept Catalent Inc. Speaking today for Catalent are myself John Chiminski and Wetteny Joseph. Catalent inc Q4 2021 earnings call dated Aug.

Prior to joining Catalent she served as the Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services Inc. With over 80 years serving the industry Catalent has proven expertise in bringing more customer products to market faster enhancing product performance and ensuring reliable clinical and. Catalent is the 1 partner in helping pharmaceutical biotech and consumer health innovators develop deliver and supply superior products that improve peoples lives.

Please see our agenda on Slide 2 of our accompanying presentation which is available on our Investor Relations website. 1 732 537 6325 Fax. 14 Schoolhouse Road Somerset NJ 08873 Phone.

Catalent today announced that it has reached an agreement to acquire Bettera Holdings LLC a major manufacturer in the high-growth gummy soft chew and lozenge segments of the nutritional supplements market for 1 billion. Investor Relations Dept Catalent Inc. 14 Schoolhouse Road Somerset NJ 08873 Phone.

1 732 537 6325 Fax. 1 732 537 5932 Mail. Catalent Chris Halling 44 07580 041073 chrishallingcatalent.

1 732 537 5932 Mail. In addition to leading the Investor Relations function Mr. Paul Surdez– Vice President of Investor Relations Good morning everyone and thank you for joining us today to review Catalents third quarter 2021 financial results.

Paul Surdez– Vice President Investor Relations Good morning everyone and thank you for joining us today to review Catalents fourth. Investors Novavax Inc. Catalent Appoints Harold Jenkins as General Manager of its Clinical Supply Facility in Philadelphia.

NYSECTLT Q4 2021 Earnings Conference Call August 30 2021 0815 AM ET Company Participants Paul Surdez – VP IR John Chiminski – Chairman and CEO Thomas Castellano – SVP.


Arcturus And Catalent To Manufacture Mrna Based Covid 19 Vaccine


Catalent Inc Catalent Inc Reports Fourth Quarter Fiscal 2021 Results


Catalent Further Strengthens Biologics Business With Key Senior Appointments Business Wire


Catalent To Acquire Gene Therapy Leader Paragon Bioservices Inc For 1 2 Billion Catalent Biologics


Definitive Proxy Statement


About Catalent Pharma Solutions


78sdapklulqyem


About Catalent Pharma Solutions


Catalent Pharma Solutions Joins Pboa Pharma Biopharma Outsourcing Association


Catalent Biologics Turns To Track Trace To Keep Compliant


News And Events Catalent


Catalent Capabilities


424b1


Catalent Starts Manufacture Of Passage Bio S Lead Gene Therapy Products

Leave a Reply